

IPOs

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
PCL (SG Cap Technology) (241820)	23-Feb-17	Geumcheon-gu, South Korea	Developer of a protein micro-array platform to screen HIV, HCV, HBV and other infectious diseases.	12.59	Korea Investment & Securities
Oncopeptides (ONCO)	22-Feb-17	Stockholm, Sweden	Developer of an anti-cancer drug that has the ability to achieve higher concentrations of cancer killing molecules in cancer cells without a corresponding increase in damage to the patient's bone marrow.	73.08	ABG Sundal Collier, Carnegie Investment Bank, DNB Markets

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Muse Bio	28-Feb-17	Boulder, CO	Early Stage VC	Developer of a genome engineering technology designed to enable high throughput massively-multiplexed CRISPR editing of proteins, pathways and genomes.	23.00	Venrock
Motus GI Medical Technologies	28-Feb-17	Nazareth, Israel	Later Stage VC	Developer of a single-use endoscopy device that attaches to a standard colonoscope and creates turbulence within the colon using water jets, enabling physicians to clean, visualize, diagnose and, if necessary, treat an inadequately prepped colon.	30.00	Perceptive Advisors
Cardiowise	28-Feb-17	Fayetteville, AR	Angel	Provider of a non-invasive cardiac magnetic resonance imaging analysis software created for early diagnosis of diseases.	0.23	Undisclosed Investors
Addex Therapeutics (ADXN)	28-Feb-17	Geneva, Switzerland	PIPE	Developer of an allosteric modulator drug discovery platform created to offer biopharmaceutical products for the treatment of neurological disorders.	3.00	Herculis Partners, Undisclosed Investors
SynGen	27-Feb-17	Sacramento, CA	Later Stage VC	Developer of single use disposable cartridges to capture stem and progenitor cells from peripheral and umbilical cord blood, bone marrow and adipose tissue.	3.00	Undisclosed Investors
Pierre Guérin	27-Feb-17	Mauzé-sur-le-Mignon, France	PE Growth/Expansion	Manufacturer of engineered industrial products, such as stainless steel tanks and bioreactors.	Undisclosed	Capzantine
Pharma Two B	27-Feb-17	Rehovot, Israel	Later Stage VC	Developer of drugs for the treatment of Parkinson's disease and cancer.	30.00	Israel Biotech Fund
Neolight	27-Feb-17	Scottsdale, AZ	Angel	Developer of phototherapy beds to cure jaundice in pre-term and full-term babies.	1.00	Undisclosed Investors
MyoTherix	27-Feb-17	Union City, CA	Early Stage VC	Developer of therapeutics for Duchenne muscular dystrophy and other muscle disorders.	8.43	Undisclosed Investors
Kinnos	27-Feb-17	Brooklyn, NY	Seed Round	Developer of an infectious disease decontamination method using a powdered additive for disinfectants, enabling healthcare workers and patients to prevent disease outbreak through clothing and other surfaces.	1.00	Georgica Advisors, New York Angels, Venture Well
Illustris Pharmaceuticals	27-Feb-17	Palto Alto, CA	Early Stage VC	Developer of molecule delivery technology designed to deliver ingredients that can permeate tissue structures.	5.00	Undisclosed Investors
Exonics Therapeutics	27-Feb-17	Boston, MA	Seed Round	Developer of a gene editing treatment created to find a cure for Duchenne muscular dystrophy.	5.00	CureDuchenne Ventures

Compiled by: Morgan Reape

Source: Pitchbook

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Congenica	27-Feb-17	Cambridge, United Kingdom	Early Stage VC	Developer of a clinical genome analysis platform that processes genome wide data sets to detect mutations by filtering clinically relevant variants and deep clinical phenotyping, enabling clinicians to provide actionable interpretation of genetic disease for patients.	9.99	Cambridge Innovation Capital
Xenex Disinfection Services	24-Feb-17	San Antonio, TX	Later Stage VC	Developer of a portable device that uses pulsed xenon UV light to kill bacteria and viruses in healthcare facility rooms.	38.00	Essex Woodlands
Samark Technology	24-Feb-17	Sarasota, FL	Angel	Developer of micro-invasive video needle syringes intended to visualize orthopedic surgeries.	0.10	Undisclosed Investors
RapidConnect	24-Feb-17	Raleigh, NC	Angel	Developer of a mobile app and Web interface designed by physicians enabling real-time secure communications between the clinical care team.	0.77	Undisclosed Investors
Lung Therapeutics	24-Feb-17	Austin, TX	Early Stage VC	Developer of pharmaceutical products targeting niche, orphan drug indications for lung injury and disease with an emphasis on fibrosis.	3.48	UT Horizon Fund, Undisclosed Investors
Inprentus	24-Feb-17	Champaign, IL	Early Stage VC	Developer of ultrahigh precision diffraction gratings for X-Ray analysis and imaging.	0.54	Serra Ventures, Undisclosed Investors
CardioSolv Ablation Technologies	24-Feb-17	Baltimore, MD	Angel	Developer of a heart simulation software that guides therapies for the treatment of patients with ventricular tachycardia.	0.05	Undisclosed Investors
Agilis Biotherapeutics	24-Feb-17	Cambridge, MA	Early Stage VC	Developer of DNA-based therapeutics using the transformative approach based on delivering a corrected copy of a naturally occurring gene directly to targeted cells designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system.	12.67	Undisclosed Investors
Qool Therapeutics	23-Feb-17	Menlo Park, CA	Early Stage VC	Provider of a non-invasive system to induce therapeutic hypothermia for preservation of tissue following a heart attack, stroke and traumatic brain injury.	6.70	Western Technology Investment
Fusion Pharmaceuticals	23-Feb-17	Hamilton, Canada	Early Stage VC	Developer of novel targeted alpha therapeutics for chemotherapy resistant cancers created to leverage radioactivity in relatively low doses to attack cancer cells.	25.00	Johnson & Johnson Innovation

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Front Range Biosciences	23-Feb-17	Boulder, CO	Seed Round	Provider of known agricultural biotechnologies such as tissue culture, cryopreservation, genomics, and marker-assisted breeding to enable cannabis cultivators to improve their yields, reduce disease, and create novel strains.	1.50	Intuitive Private Equity, Salveo Capital, Sand Hill Angels
Theragen	22-Feb-17	Manassas, VA	Early Stage VC	Developer of medical devices to treat osteoarthritis and apply therapeutic energy technologies for healing and pain relief.	9.14	Ballast Point Ventures, Undisclosed Investors
PMV Pharmaceuticals	22-Feb-17	Cranbury, NJ	Early Stage VC	Developer of small molecule drugs that induce an organized program of cellular death, enabling cancer patients to restore the body's natural defense mechanism and prevent the proliferation of potentially cancerous cells.	73.73	Topspin Ventures, Euclidean Capital
PharmacoPhotonics	22-Feb-17	Carmel, IN	Angel	Developer of detection devices providing a measure of the kidney's function or glomerular filtration rate in 15 to 30 minutes, enabling hospitals, cardiac catheterization labs and physician to treat acute kidney injuries and chronic kidney diseases.	3.00	Undisclosed Investors
Oncternal Therapeutics	22-Feb-17	San Diego, CA	Early Stage VC	Developer of novel therapies for both rare and common cancers.	18.40	Undisclosed Investors
InSilico Medicine	22-Feb-17	Baltimore, MD	Early Stage VC	The company uses deep learning technology for drug discovery and drug re-purposing for aging and age-related diseases, allowing for the identification of molecules that may be effective against a variety of cancers as well as metabolic, cardiovascular and central nervous system diseases.	10.00	Undisclosed Investors
Imago BioSciences	22-Feb-17	San Francisco, CA	Early Stage VC	Provider of a treatment designed to translate state-of-the-art science into novel medicines for the treatment of cancer and other diseases of gene expression.	40.50	Clarus Ventures
BookDoc	22-Feb-17	Petaling Jaya, Malaysia	Seed Round	Provider of an integrated online ecosystem for local and overseas health travelers.	2.00	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Nanox Imaging	21-Feb-17	Gibraltar, Gibraltar	Angel	Developer of next generation X-ray emitters made from nanotechnology, specializing in features like high current density, ultra-fast switching, no space-charge limit and highly uniform emission, enabling engineers to apply this technology in medical imaging.	1.11	Undisclosed Investors
Nabriva Therapeutics (NBRV)	21-Feb-17	Vienna, Austria	PIPE	Provider of research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.	Undisclosed	Undisclosed Investors
Harmonigenic	21-Feb-17	Rochester, NY	Angel	Developer of an optical assay technology that is useful in predicting recurrence of breast cancer.	0.05	Undisclosed Investors
Faraday Pharmaceuticals	21-Feb-17	Seattle, WA	Early Stage VC	Operator of a biopharmaceutical company designed to focus on the research and development of elemental reducing agents for critical care medicine.	32.61	WRF Capital, Osage Partners, ARCH Venture Partners
Canary Speech	21-Feb-17	Spanish Fork, UT	Angel	Provider of a machine learning-based speech recognition technology that helps monitor speech for early signs of various neurological conditions, such as dementia and Alzheimer's disease.	0.08	Undisclosed Investors
Bristol-Myers Squibb Company (BMY)	21-Feb-17	New York, NY	PIPE	Developer of drugs for several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.	Undisclosed	Carl Icahn
Affigen	21-Feb-17	Saint Louis, MO	Early Stage VC	Developer of therapeutics targeting cell lineage-specific tumor proteins that maximize both anti-tumor activity and safety in patients with critically unmet medical needs.	17.00	Black Beret Life Sciences
Vault Dragon	20-Feb-17	Singapore, Singapore	Seed Round	Provider of a leading clinic management system designed to manage medical records.	1.16	Golden Equator Capital, Raging Bull
Realist Pharma	20-Feb-17	Toronto, Canada	Early Stage VC	Developer of cell therapies and cancer vaccines through active immune strategies that utilize the patient's own immune defenses to target widespread tumor markers present in a large number of cancers.	0.20	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
QRepublik	20-Feb-17	Moscow, Russia	Accelerator/ Incubator	Developer of a wearable medical device designed to track contact information about patients and notify their family members about their location during medical emergencies.	0.35	Russian Venture Company
Pacifica Labs	20-Feb-17	San Francisco, CA	Seed Round	Developer of a mental health application based on Cognitive Behavioral Therapy with relaxation and wellness techniques that are distilled down into simple, quick, daily activities to provide a way for people to track their progress, helping them address stress, anxiety and depression at a gradual pace.	Undisclosed	LEO Innovation Lab
Modus Therapeutics	20-Feb-17	Stockholm, Sweden	Later Stage VC	Developer of an anti-adhesive and anti-inflammatory drug designed through a chemical depolymerization of heparin that can be used in treatment of acute painful crisis in sickle cell disease patients.	3.60	Karolinska Development
iScribes	20-Feb-17	Durham, NC	Angel	Provider of virtual medical scribe services.	1.11	Undisclosed Investors
CrowdMed	20-Feb-17	San Francisco, CA	Early Stage VC	Provider of an online medical community that offers a collaborative approach for solving complex medical cases for patients who have been suffering from unresolved, chronic symptoms for months or even years, enabling patients to explore all possible medical diagnoses and services.	Undisclosed	Arab Angel, Mindset Ventures
CrossTx	20-Feb-17	Bozeman, MT	Early Stage VC	Provider of a cloud-based healthcare coordination platform designed to improve overall patient experience.	0.74	Frontier Fund 2
Voxello	17-Feb-17	Coralville, IA	Early Stage VC	Developer of a suite of input devices such as microphones, proximity switches, infrared detectors, pressure switches with proprietary software and a communication device called Noodle, enabling hospitalized patients to communicate with their caregivers.	1.20	Dakota Venture Group, Wellmark Blue Cross and Blue Shield of Iowa
Hennepin Life Sciences	17-Feb-17	Plymouth, MN	Angel	Provider of naturally-derived anti-infective compounds for the prevention and treatment of infectious diseases, including vaginal candidiasis, urinary tract infections and skin and soft tissue infections.	1.85	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Empire Medicinals	17-Feb-17	Rochester, NY	Angel	Developer of organic natural products, herbal medicinal products and natural health and medicinal supplements primarily made from medicinal mushrooms that help in supporting the immune system health, vitality and stamina and also helps to manage stress effectively.	0.01	Undisclosed Investors
DiFusion Technologies	17-Feb-17	Austin, TX	Angel	Developer of metallic ion therapeutic agents technology designed for antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold construction and increased angiogenesis.	2.43	Undisclosed Investors
Cyrus Biotechnology	17-Feb-17	Seattle, WA	Early Stage VC	Provider of an easy-to-use version of rosetta interface that offers protein structure prediction and protein designing, enabling its users in molecular, homology and protein modeling.	1.58	WRF Capital, Undisclosed Investors
Xcell Biosciences	16-Feb-17	San Francisco, CA	Early Stage VC	Developer of research tools and diagnostic solutions that replicate physiologically relevant conditions, empowering researchers and drug developers in transfection and gene editing efficiencies in primary cell populations for regenerative medicine and cell-based therapy applications.	12.00	HBM Healthcare Investments
Nativis	16-Feb-17	Seattle, WA	Angel	Developer of a non-invasive and non-thermal medical device for the treatment of solid tumors.	9.62	Undisclosed Investors
Keriton	16-Feb-17	Philadelphia, PA	Seed Round	Provider of breast-milk management and analytics software for neonatal ICUs, designed to improve nurse productivity and increase expression of breast milk in lactating mothers.	1.00	BioAdvance
F1 Oncology	16-Feb-17	San Diego, CA	Early Stage VC	Owner and operator of a biotechnology company specializing in T-cell immunotherapy research for developing drugs to treat cancer induced viruses and antigens.	44.00	F1 BioVentures, Bridgewest Group, Sinobioway Group, SunTerra Capital, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Checkmate Pharmaceuticals	16-Feb-17	Cambridge, MA	Early Stage VC	Developer of cancer immunotherapies designed to combine the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response, enabling treatment of patients with advanced cutaneous melanoma.	25.00	Sofinnova Ventures, venBio, Undisclosed Investors
Surrozen	15-Feb-17	South San Francisco, CA	Early Stage VC	Developer of regenerative drugs that accelerate the repair and renewal of human tissues through signal transduction pathways.	33.00	The Column Group
Orreco	15-Feb-17	Los Angeles, CA	Later Stage VC	Provider of bio-marker analysis intended to optimize athlete performance, enabling players to reduce the incidence of illness and injury.	2.00	True Ventures
OncoMark	15-Feb-17	Dublin, Ireland	Later Stage VC	Developer of a device that detects early stage breast cancer, enabling clinicians to determine treatment options for their patients.	2.24	Kernel Capital, Irrus Investments, Halo Business Angel Network
Omage Labs	15-Feb-17	Seattle, WA	Angel	Provider of a healthcare and wellbeing management platform intended to track and manage the health of senior citizens.	0.03	Undisclosed Investors
mClinica	15-Feb-17	Singapore, Singapore	Later Stage VC	Provider of data, analytics and patient engagement tools designed to unite multinational pharmaceutical companies, governments, NGOs, and academic institutions on a common platform, provide access to new sources of data, and allow for the deployment of data-driven programs.	6.30	Iunitus Impact
Luma Therapeutics	15-Feb-17	Millbrae, CA	Angel	Developer of light therapies designed to treat inflammatory skin disorders, such as psoriasis.	2.05	Undisclosed Investors
Jecure Therapeutics	15-Feb-17	San Diego, CA	Early Stage VC	Developer of small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis and liver fibrosis.	20.00	Versant Ventures
GluSense	15-Feb-17	Rehovot, Israel	Later Stage VC	Developer of a minimally invasive device that offers accurate glucose measurement for a full year with significantly fewer blood glucose calibrations.	0.54	T1D Fund

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Encoda	15-Feb-17	Blue Bell, PA	Angel	Developer of a medical revenue cycle automation tool that offers back office staff with features such as revenue collection and management, client billing systems, medical insurance claim handling and other similar services.	1.50	Undisclosed Investors
Carmat (ALCAR)	15-Feb-17	Vélizy Villacoublay CEDEX, France	PIPE	Designer and developer of a bio-compatible, auto-regulated artificial heart designed to be as close as possible to the human heart.	31.89	AMF
Caerus Discovery	15-Feb-17	Manassas, VA	Accelerator/ Incubator	Developer of antibody and therapeutic products for the treatment of human diseases, including infectious, inflammatory, metabolic, neurological and malignant diseases.	0.05	Prince William Science Accelerator
Avenu Medical	15-Feb-17	San Juan Capistrano, CA	Later Stage VC	Developer of an innovative, image-guided, single catheter system used to percutaneously create an arteriovenous fistula for hemodialysis access, enabling physicians to treat patients with chronic kidney diseases.	13.11	Undisclosed Investors
Audio Bionics International	15-Feb-17	Los Angeles, CA	Angel	Provider of tinnitus sound therapy intended to effectively suppress tinnitus.	0.86	Undisclosed Investors
3D Vision Systems	15-Feb-17	Ann Arbor, MI	Angel	Manufacturer of medical equipment and supplies.	0.10	Undisclosed Investors
Updox	14-Feb-17	Dublin, OH	Later Stage VC	Provider of a healthcare CRM connectivity platform designed to find pragmatic ways for providers to adapt to the changing healthcare landscape.	11.20	Undisclosed Investors
Tryton Medical	14-Feb-17	Durham, NC	Later Stage VC	Developer of a novel cobalt chromium stent system that offers a dedicated strategy to deploy the side branch artery using a standard single wire balloon-expandable stent delivery system, enabling its clients to treat bifurcation lesions in coronary artery diseases.	4.00	Undisclosed Investors
Sense.ly	14-Feb-17	San Francisco, CA	Early Stage VC	Developer of a patient engagement platform that leverages video, voice and body recognition, sensor integration and augmented reality to enable continuous monitoring and analysis of patient's health after a discharge.	8.00	Mayo Clinic, Chengwei Capital
Q Care International	14-Feb-17	Marietta, GA	Angel	Developer of needle removal and disposal systems.	3.85	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
HemoSonics	14-Feb-17	Charlottesville, VA	Angel	Developer of a point-of-care diagnostic platform that offers actionable information to guide the management of critical bleeding and clotting.	22.63	Undisclosed Investors
Treos Bio	13-Feb-17	London, United Kingdom	Early Stage VC	Developer of immunotherapy vaccines intended for the destruction of cancer cells.	8.00	BXR Group, Undisclosed Investors
SigTuple	13-Feb-17	Bangalore, India	Early Stage VC	Developer of hardware and software on artificial intelligence technology designed to digitize pathological tests.	5.80	Accel Partners
Retriever Medical Dental Payments	13-Feb-17	Valhalla, NY	PE Growth/Expansion	Provider of healthcare payment solutions allowing providers to integrate payment processing workflow and data with their existing practice management software or ERP systems.	Undisclosed	TA Associates
Hygieia	13-Feb-17	Ann Arbor, MI	Later Stage VC	Developer of a diabetes insulin guidance system created to enhance and simplify insulin therapy.	0.57	Blue Cross Blue Shield of Michigan
Forerunner Medical	13-Feb-17	Shanghai, China	Later Stage VC	Developer and manufacturer of medical devices created on low temperature radio-frequency ablation and domestic clinical data that are used for the treatment of cancer in liver, lung, thyroid, breast and other organs.	Undisclosed	Medtronic, Sequoia Capital China
AltheaDx	13-Feb-17	San Diego, CA	Later Stage VC	Developer of a pharmacogenetics product testing portfolio.	6.00	Undisclosed Investors
UAS Laboratories	10-Feb-17	Wausau, WI	PE Growth/Expansion	Manufacturer of semi-finished and raw-material supplies of probiotic-based supplements.	21.25	Undisclosed Investors
SynergEyes	10-Feb-17	Carlsbad, CA	Later Stage VC	Provider of hybrid contact lenses for eye conditions like astigmatism, presbyopia, myopia, hyperopia and keratoconus that are made by combining new high-Dk materials and vision-optimized designs.	3.53	Undisclosed Investors
GeneCast Biotechnology	10-Feb-17	Beijing, China	Early Stage VC	Provider of a DNA sequencing platform that offers individual drug selection and gene detection, efficacy monitoring and liquid biopsy for the detection of circulating tumor DNA of lung, colon, liver and breast cancers.	18.00	Tsinghua Holdings
ZSX Medical	9-Feb-17	Philadelphia, PA	Later Stage VC	Developer of Zip-stitch, a surgical closure system that is an alternative to sutures for major surgeries.	1.58	Keiretsu Forum, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
VIA Global Health	9-Feb-17	Seattle, WA	Accelerator/ Incubator	Provider of an e-commerce and logistics platform designed to connect medical distributors with affordable medical devices and supplies.	0.15	500 Startups
Trainer Rx	9-Feb-17	Walnut Creek, CA	Early Stage VC	Developer of a medical software designed for healthcare providers who treat musculoskeletal injury that delivers individualized rehabilitation and recovery pathways with step-by-step guidance from injury through recovery.	3.86	Undisclosed Investors
Therapydia	9-Feb-17	Mill Valley, CA	Early Stage VC	Operator of an online community intended to connect physical therapists, facilitate the exchange of ideas and mobilize physical therapy around key issues like reimbursement and direct access.	8.92	Peterson Partners, de Anda Capital, David Brown
OrthoSera	9-Feb-17	Krems an der Donau, Austria	Early Stage VC	Developer of serum-based orthobiologics created to provide treatment of dental and musculoskeletal indications.	Undisclosed	FastVentures
Nanospectra Biosciences	9-Feb-17	Houston, TX	Later Stage VC	Developer of AuroLase Therapy which combines the unique physical and optical properties of AuroShell particles with a near infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue.	2.03	Undisclosed Investors
MolecularMD	9-Feb-17	Portland, OR	Later Stage VC	Provider of molecular diagnostic products and services to support clinical development, regulatory approval and commercialization of targeted cancer therapies.	2.07	ClearWell Group, Undisclosed Investors
Intelligent Fingerprinting	9-Feb-17	Cambridge, United Kingdom	Later Stage VC	Developer of a portable fingerprint-based drug screening system.	3.64	Undisclosed Investors
Flow Forward Medical	9-Feb-17	Olathe, KS	Later Stage VC	Developer of the Arteriovenous Fistula Eligibility system, a small, temporary, external blood pump designed to stimulate flow-mediated vein dilation, enabling hemodialysis patients to reduce morbidity and mortality.	7.00	Undisclosed Investors
Evotec (EVT)	9-Feb-17	Hamburg, Germany	PIPE	Developer of drugs in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases.	96.18	Novo
Biomarker.io	9-Feb-17	San Francisco, CA	Accelerator/ Incubator	Provider of a digital health platform designed to track and decode impact of dietary changes on health and performance.	0.15	500 Startups

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Avails Medical	9-Feb-17	Menlo Park, CA	Early Stage VC	Developer of non-invasive therapeutic drug monitoring devices to determine optimum drug dosage in epileptic patients.	6.86	The Explore Group, Undisclosed Investors
Arthritis Innovation	9-Feb-17	Toronto, Canada	Angel	Developer of drug delivery copolymers created to meet clinical needs in the fields of orthopedics and arthritis.	0.32	Undisclosed Investors
Ambient Clinical Analytics	9-Feb-17	Rochester, MN	Early Stage VC	Developer of patient management and clinical support tools designed to reduce medical errors for data assimilation, communication and analytics.	3.93	Undisclosed Investors
Welltrack	8-Feb-17	Fredericton, Canada	Accelerator/ Incubator	Provider of on-demand online therapy for mental health issues specializing in providing computerized cognitive behavioral therapy for the treatment of stress, anxiety and depression.	Undisclosed	500 Startups
Vitruvian Networks	8-Feb-17	Menlo Park, CA	Early Stage VC	Developer of software for scaling and digital services for cell and gene therapies.	13.81	GE ventures, Drraper Fisher Jurvetson, Mayo Clinic Ventures, Undisclosed Investors
Phynd Technologies	8-Feb-17	Dallas, TX	Early Stage VC	Provider of a management platform that enables hospitals and health systems to manage their licensed provider data profiles across all core clinical, financial and operational IT systems.	0.25	Rex Health Ventures
Hospi	8-Feb-17	Newark, CA	Later Stage VC	Developer of a rectal catheter device designed to facilitate administration of liquids or medications.	3.49	Undisclosed Investors
HistoSonics	8-Feb-17	Ann Arbor, MI	Later Stage VC	Provider of a histotripsy platform that offers non-invasive, non-thermal surgery using pulsed sound waves to induce cavitation that mechanically destroys tissue, tumors and plaque at the cellular level.	8.26	Undisclosed Investors
Genomind	8-Feb-17	King of Prussia, PA	Later Stage VC	Developer of personalized medicines created to advance mental healthcare through genetic testing.	11.00	Silicon Valley Bank, Undisclosed Investors
Endoshape	8-Feb-17	Boulder, CO	Later Stage VC	Developer of polymer-based vascular embolization products with a focus on the coil embolization and occlusion market.	4.00	Undisclosed Investors

Compiled by: Morgan Reape

Source: Pitchbook

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Atriva Therapeutics	8-Feb-17	Tübingen, Germany	Seed Round	Developer of influenza therapy intended to fight against seasonal and pandemic influenza.	Undisclosed	Stichting Participatie Atriva, High-Tech Gründerfonds
Applied Therapeutics	8-Feb-17	New York, NY	Early Stage VC	Developer of a disease treatment technology platform that offers opportunities for effective drug development against diseases.	6.07	Alexandria Real Estate Equities
Vesiflo	7-Feb-17	Redmond, WA	Angel	Developer of a replaceable urinary prosthesis that help women suffering from impaired detrusor contractility to push urine out of the bladder.	2.40	Undisclosed Investors
Recursion Pharmaceuticals	7-Feb-17	Salt Lake City, UT	Early Stage VC	Operator of a drug discovery company that combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease that can be modeled at the cellular level.	55.10	Lux Capital, Square 1 Bank
Prexton Therapeutics	7-Feb-17	Geneva, Switzerland	Early Stage VC	Developer of medical drugs and therapeutics for brain disorders that offers an alternative to the stimulation of the dopaminergic system through a novel molecule mGluR4 PAM series.	30.89	Forbion Capital Partners, Seroba Life Sciences
Laminate Medical Technologies	7-Feb-17	Tel-Aviv, Israel	Angel	Developer of a blood vessel support device created for improving renal vascular procedures.	8.00	Haisco Pharmaceutical Group, Undisclosed Investors
Connexions Asia	7-Feb-17	Singapore, Singapore	Early Stage VC	Provider of an employee benefits and workplace wellness platform for employees designed to offer a fixed benefits wallet to choose the most relevant mix of insurance and wellness services from a wide range of providers to suit their personal needs.	25.00	B Capital Group, EDB Investments
BrainSpec	7-Feb-17	Boston, MA	Accelerator/ Incubator	Operator of a health technology company created to diagnose brain disorders using an efficient and radiation-free approach that involves software and magnetic resonance spectroscopy.	0.12	Techstars
BioMarcK Pharmaceuticals	7-Feb-17	Durham, NC	Later Stage VC	Developer of drugs for the treatment of pulmonary diseases associated with the over-secretion of mucus and pulmonary inflammation.	7.75	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Acticor Biotech	7-Feb-17	Paris, France	Early Stage VC	Provider of therapeutic services for the treatment of emergency stroke.	3.09	Anaxago, ARMESA, Cap Decisif Management, Undisclosed Investors
ProMetic Life Sciences (PLI)	6-Feb-17	Laval, Canada	PIPE	Developer of therapeutics products for fibrosis, anemia, neutropenia, cancer and autoimmune disease/inflammation.	21.05	California Capital Equity
CureApp	6-Feb-17	Tokyo, Japan	Early Stage VC	Developer of a disease treatment app created to progress the utilization of ICT and AI for medical and nursing care.	3.36	Beyond Next Ventures
Chèque Santé	6-Feb-17	Montpellier, France	Early Stage VC	Provider of Web and payment services for the healthcare sector designed to dedicate health prevention and well-being.	5.54	SORIDEC, iXO Private Equity
Banyan Biomarkers	6-Feb-17	Alachua, FL	Later Stage VC	Developer of diagnostic products to detect traumatic brain injuries.	11.40	Undisclosed Investors
AZTherapies	6-Feb-17	Boston, MA	Early Stage VC	Developer of combination drug therapies to prevent and manage disease progression in persons with early to moderate Alzheimer's disease.	16.05	Undisclosed Investors
Avalon Healthcare Solutions	6-Feb-17	Tampa, FL	Early Stage VC	Provider of laboratory benefits management services by reducing unnecessary utilization, optimizing network and increasing scores for payers through quality improvement.	29.27	Echo Health Ventures, BlueCross BlueShield of South Carolina, Fransisco Partners, Undisclosed Investors
Ark Biosciences	6-Feb-17	Shanghai, China	Early Stage VC	Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis.	Undisclosed	Bioventure Investment Management

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
Abbisko Therapeutics	6-Feb-17	Shanghai, China	Early Stage VC	Provider of drug research and development services for the treatment of cancer.	28.00	Lilly Asia Ventures, Sinopharm Capital, TF Capital
myNEXUS	3-Feb-17	Brentwood, TN	PE Growth/Expansion	Provider of healthcare management services that monitor a patient's health status and generates analytical reports intended to connect individuals to caregivers.	1.50	Undisclosed Investors
Comprehend Systems	3-Feb-17	Redwood City, CA	Later Stage VC	Provider of a single cloud-based suite that offers real-time patient insights, on-time milestones and improved data quality with powerful data aggregation, monitoring, analytics and collaboration capabilities to clinical trial teams.	14.80	Eminence Capital
Vividion Therapeutics	2-Feb-17	San Diego, CA	Early Stage VC	Developer of a novel drug discovery platform that applies chemical proteomics to expand the druggable proteome and address difficult targets to bring new, transformative treatments to patients with serious illnesses, enabling customers to create proteome-wide drug interaction maps for simultaneous target engagement and global selectivity profiling.	50.00	ARCH Venture Partners, Versant Ventures
Tarveda Therapeutics	2-Feb-17	Watertown, MA	Later Stage VC	Developer of novel cancer therapies created to treat solid tumors for patients with neuroendocrine cancers.	30.00	Versant Ventures
Slope.io	2-Feb-17	Chattanooga, TN	Seed Round	Provider of specialized, software-driven logistics services to clinical researchers.	0.90	Vivek Garipalli
Serina Therapeutics	2-Feb-17	Huntsville, AL	Angel	Developer of a therapeutics and drug delivery platform based on polymer technology designed to treat cancer, inflammation, pain and metabolic disorders.	4.06	Undisclosed Investors
InnovaTel	2-Feb-17	Erie, PA	PE Growth/Expansion	Provider of telepsychiatry services intended to increase the accessibility of psychiatric care in rural areas.	2.00	Canyon Healthcare Partners
Coriell Life Sciences	2-Feb-17	Camden, NJ	Seed Round	Provider of a healthcare management system that offers storage of genomic data, expert interpretation and an interchange framework that delivers clinically-relevant genomic interpretation at the point-of-care.	1.20	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
ApcinteX	2-Feb-17	Cambridge, United Kingdom	Early Stage VC	Developer of an anticoagulant protein that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia.	17.48	Medicxi Ventures, Imperial Innovations Group
VisCardia	1-Feb-17	Beaverton, OR	Early Stage VC	Developer of an implantable electronic sensor and electrode system for delivering chronic electrical stimulation for treating thoracic pressure augmentation.	0.40	Kinetic Capital Partners
Sidekick (Health Behavior Change Platform)	1-Feb-17	Gothenburg, Sweden	Early Stage VC	Developer of a health engagement and analytics platform that combines gamified engagement methods with health screening and analytics for the prevention and treatment of lifestyle related chronic diseases.	1.50	Frumtak Ventures
PointClickCare	1-Feb-17	Mississauga, Canada	PE Growth/Expansion	Developer of a SaaS cloud-based electronic health records software designed to help long-term post-acute care and senior living providers streamline and manage the complete lifecycle of resident care.	85.00	Gdragoner Investment Group, JMI Equity
Immunic Therapeutics	1-Feb-17	Planegg-Martinsried, Germany	Early Stage VC	Provider and developer of small molecule immune modulators that block T-helper type 1- and type 17-mediated immune and autoimmune responses to treat conditions including inflammatory bowel disease and psoriasis.	23.11	LifeCare Partners, Life Sciences Partners
HealthReveal	1-Feb-17	New York, NY	Early Stage VC	Developer of a cloud-based, clinical analytics platform designed to continually monitor and analyze patient physiology and care by integrating multiple real-time streams of clinical, operational and biometric data to ensure adherence to evidence-based care guidelines by clinicians and patients.	10.80	GE ventures, Draper Fisher Jurvetson, Mayo Clinic Ventures, Undisclosed Investors
Glide Pharmaceutical	1-Feb-17	Oxfordshire, United Kingdom	Later Stage VC	Developer of needle-free drug delivery platforms focused on solid dose formulations of therapeutics and vaccines.	4.00	Invesco Perpetual, Oxford Technology, Oxford Capital Partners

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Lead Investor(s)
DVM Systems	1-Feb-17	Greeley, CO	Angel	Developer of temperature monitoring equipment that provides accurate heat and ovulation detection.	0.75	Undisclosed Investors
CoheroHealth	1-Feb-17	New York, NY	Early Stage VC	Developer and provider of a connected healthcare device platform enabling respiratory patients to use a mobile device to monitor health and coordination between patients and their care providers.	13.35	Three Leaf Ventures
Allurion Technologies	1-Feb-17	Natick, MA	Later Stage VC	Developer of Elipse Balloon, a thin, flexible polymer film that is delivered in a swallowable capsule, eliminating the need for surgery, endoscopy or anesthesia, enabling overweight and obese individuals to reduce weight.	25.02	Romulus Capital

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Takara Bio USA	Wafergen Bio-Systems	Fremont, CA	28-Feb-17	Operator of a biotechnology company that develops, manufactures and sells systems for gene expression, genotyping and stem cell research for life sciences, pharmaceutical drug discovery and diagnostic products industries.	50.00
TIDI Products	Posey	Arcadia, CA	28-Feb-17	Manufacturer of products for fall management, wound management, bed safety, seating and positioning to create a safer patient environment.	Undisclosed
A2 Acquisition	Medicenna Therapeutics	Vancouver, Canada	27-Feb-17	Developer of novel cytokines for the targeted treatment of cancer, autoimmune disease and fibrosis.	Undisclosed
Johnson & Johnson	Abbott Medical Optics	Santa Ana, CA	27-Feb-17	Manufacturer of intraocular lenses, laser-vision correction systems, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgeries.	4325.00
Kernel	Kendall Research Systems	Cambridge, MA	24-Feb-17	Developer of hardware instrumentation and software solutions for in vivo neuroscience research.	Undisclosed
Lumenis	Focus Medical (Laser Business)	Bethel, CT	24-Feb-17	Manufacturer of electromedical, electrotherapeutic apparatuses and surgical and medical instruments.	Undisclosed
Integra LifeSciences Holdings	Derma Sciences	Princeton, NJ	24-Feb-17	Provider of wound care, wound closure, burn care and skin care products.	204.00
One Call Care Management	High Line Health	New York, NY	23-Feb-17	Developer of a healthcare analytics and data visualization platform that distills large quantities of data into straightforward, actionable reporting.	Undisclosed
Aviva Systems Biology	GenWay BioTech	San Diego, CA	23-Feb-17	Provider of customized products and services including antigen preparation, antibody development and immunoassays for the research community.	Undisclosed
OncoDNA	BioSequence	Valencia, Spain	23-Feb-17	Provider of cutting edge tumor molecular profiling technologies intended to offer cancer diagnosis and genomics ultrasequencing services.	Undisclosed
My Marijuana Canada	Sublime Culture	Montreal, Canada	22-Feb-17	Producer of cannabis intended for medical purposes regulations.	Undisclosed
Sanitas	Healthia	Madrid, Spain	21-Feb-17	Developer of digital health services platform software that offers a footprint study, echo-cardiogram, effort test, stress test, sports training, nutrition assessment and other related services.	Undisclosed
Kalytera Therapeutics	Talent Biotechs	Bnei-Brak, Israel	16-Feb-17	Developer of cannabidiol-based therapies for the treatment of graft versus host disease.	Undisclosed
Takeda Pharmaceutical	Ariad Pharmaceuticals	Cambridge, MA	16-Feb-17	Developer of drugs focused on small molecule medicines that target proteins and pathways involved in cancer.	5200.00

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Catalent	Accucaps Industries	Strathroy, Canada	16-Feb-17	Manufacturer of soft gelatin capsules.	75.00
Quotient Clinical	QS Pharma	Upper Chichester Township, PA	14-Feb-17	Provider of a comprehensive pharmaceutical development platform that provides a broad range of contract development and commercial manufacturing services for pharmaceutical and bio-pharmaceutical companies.	75.00
Private Investors	NexImmune	Gaithersburg, MD	14-Feb-17	Developer of novel immuno-therapeutics based on the proprietary artificial immune nanotechnology platform designed to develop immuno-therapies for a variety of cancers and other diseases.	Undisclosed
Hill-Rom Holdings	Mortara Instrument	Milwaukee, WI	14-Feb-17	Manufacturer of diagnostic cardiology, patient monitoring, electrocardiography, cardiac stress exercise testing, holter monitoring, patient monitoring, ambulatory blood pressure and other related instruments.	330.00
Anatrace	Molecular Dimensions	Suffolk, United Kingdom	14-Feb-17	Supplier of screens, reagents and other consumables used by crystallographers across the world to determine protein structures analysis in structural biology research.	Undisclosed
Symetis	Middle Peak Medical	Palo Alto, CA	14-Feb-17	Developer of a minimally invasive device to restore mitral valve competence in both functional and degenerative mitral valve disease by providing a new posterior surface onto which the anterior leaflet can properly seal.	Undisclosed
Singapore eDevelopment	iGalen International	San Diego, CA	14-Feb-17	Distributor of health supplements intended to control and manage inflammation.	Undisclosed
iGambit	HealthDatix	Saint Petersburg, FL	14-Feb-17	Developer of software that performs risk assessment and analysis of patients, produces patient reports, physician reports and summary reports for billing and identifies those patients who are at risk for chronic conditions.	Undisclosed
Cosmos Holdings	Decahedron	Harlow, United Kingdom	14-Feb-17	Wholesaler of pharmaceutical products.	1.00
PanTheryz	APS BioGroup	Phoenix, AZ	14-Feb-17	Manufacturer and producer of colostrum products and nutritional supplements.	Undisclosed
MiRagen Therapeutics	Signal Genetics	Carlsbad, CA	13-Feb-17	Provider of molecular diagnostic services for cancer patients.	60.00

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Fitesa	Pantex International	Sulmona, Italy	13-Feb-17	Manufacturer of specialty nonwovens components designed to offer customized hygiene premium materials.	Undisclosed
Modern Dental Europe	CDI Dental	Malmö, Sweden	13-Feb-17	Provider of dental care products.	4.26
TPG Capital	Mediware Information Systems	Lenexa, KS	9-Feb-17	Provider of enterprise software to healthcare and human service providers and payers across acute, non-acute and community-based sites of care.	Undisclosed
Valens GroWorks	Island Green Cure	British Columbia, Canada	9-Feb-17	Producer of marijuana drugs for medical purposes.	1.91
Weihai Weigao Equity Investment Management Company	Rad Source Technologies	Suwanee, GA	7-Feb-17	Provider of renewable, non-isotope, ionizing radiation replacements for self-shielded gamma irradiators.	Undisclosed
Quotient Clinical	SeaView Research	Miami, FL	6-Feb-17	Operator of a clinical research organization providing quality clinical pharmacology testing and laboratory services to the pharmaceutical industry.	Undisclosed
Finance Wales, Andrew Beresford, Nicola Watkins, Ian Corp, Kevin Davies	Minerva Laboratories	Cardiff, United Kingdom	6-Feb-17	Manufacturer of earmolds and ultrasonic cleaning equipment.	Undisclosed
Kirkman Group	Rose Laboratories	Bend, OR	3-Feb-17	Producer and seller of nutraceutical products intended to offer a full range of chelated vitamins and food supplements.	Undisclosed
Bionet Ventures	Navigo Protiens	Halle, Germany	3-Feb-17	Manufacturer of antibody diagnostics, imaging, therapeutics and affinity products for biopharmaceutical manufacturing.	Undisclosed
ICU Medical	Hospira (Infusion Systems Business)	Lake Forest, IL	3-Feb-17	Manufacturer of infusion and pain-management pumps designed to administer intravenous medications and fluids to patients.	900.00
Ottobock	RSL Steeper (BeBionic Prosthetics Division)	Leeds, United Kingdom	2-Feb-17	Manufacturer of prosthetic hands designed to enable amputees to perform everyday activities.	Undisclosed
Specialists on Call	NeuroCall	Miami, FL	2-Feb-17	Provider of clinical telemedicine technology and services.	Undisclosed

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Ampersand Capital Partners	Corpus Medical	Campbell, CA	2-Feb-17	Provider of contract development and manufacturing services focused on the development and commercialization of innovative interventional medical devices, catheter based-delivery systems and implants.	Undisclosed
SpecialtyCare	Trident Health Resources	Dunedin, FL	1-Feb-17	Operator of a premiere perfusion services staffing company intended to provide superior clinical care to the patient.	Undisclosed
i3	Randall Data System	Plymouth, MI	1-Feb-17	Provider of custom accounting and inventory management services specializing in the microcomputer market to a broad range of healthcare and healthcare-related organizations.	Undisclosed
Nordson	Plas-Pak Industries	Norwich, CT	1-Feb-17	Manufacturer of injection molded, single-use plastic dispensing syringes intended to improve and diversify disposable plastic packaging.	Undisclosed
Allergan	LifeCell	Somerville, NJ	1-Feb-17	Developer and marketer of soft tissue repair products for abdominal wall reconstruction, blood cell preservation, cell reconstruction and plastic surgery.	2900.00
Ecolab	Laboratoires Anios	Lille, France	1-Feb-17	Manufacturer and marketer of antimicrobial liquids and disinfectants for hospitals and clinics, healthcare professionals, dentists and industrial use.	798.85
Kaiser Permanente	Group Health Cooperative (US)	Seattle, WA	1-Feb-17	Provider of health plan administration services, such as medical coverage, Medicare advantage plans and other related services.	1800.00
Cello Group	Defined Health	Florham Park, NJ	1-Feb-17	Provider of business development strategy consulting services intended to assist clients in the pharmaceutical, biotech and healthcare investment industries.	9.00